ESMO 2018: Cabozantinib/atezolizumab combination shows encouraging clinical activity for untreated advanced RCC

Results from the phase 1b COSMIC-021 study of cabozantinib in combination with atezolizumab in people with previously untreated advanced renal cell carcinoma (RCC) were presented at the European Society for Medical Oncology (ESMO) 2018 Congress in Munich over the weekend. This dose-escalation study primarily looked at the safety of the cabozantinib + atezolizumab combination in […]

read more

ESMO 2018: Cabozantinib is effective in advanced RCC regardless of PD-L1 expression

An analysis of the data from the CABOSUN and METEOR trials has shown that expression of the PD-L1 receptor in tumour cells did not predict outcomes with cabozantinib (Cabometyx) among patients with advanced renal cell carcinoma (RCC). This analysis was presented at the European Society of Medical Oncology (ESMO) 2018 Congress in Munich over the weekend. Expression […]

read more

Cabozantinib declined for use within NHS Scotland for first-line treatment of advanced kidney cancer

We are very disappointed by the Scottish Medicines Consortium’s (SMC) decision not to recommend cabozantinib (Cabometyx) for use within NHS Scotland as a first-line treatment option for people with intermediate-risk or poor-risk advanced renal cell carcinoma (RCC). This is despite cabozantinib’s proven effectiveness at significantly extending progression-free survival in these patients compared to first-line sunitinib, as shown in the […]

read more

NICE publishes final guidance for cabozantinib for untreated advanced renal cell carcinoma

The National Institute for Health and Care Excellence (NICE) has published final guidance recommending use of cabozantinib (Cabometyx) as a treatment option for people with untreated advanced renal cell carcinoma (RCC). Clinical trials have shown that patients treated with cabozantinib in the first-line had a reduced risk of disease progression or death by 52% compared to patients treated with first-line […]

read more

Cabozantinib approved as a first-line treatment option for advanced kidney cancer on the NHS

Today, the National Institute for Health and Care Excellence (NICE) have recommended cabozantinib (Cabometyx) as a new first-line treatment option for people with intermediate- or poor-risk advanced renal cell carcinoma (RCC) for use within NHS England and Wales. Cabozantinib is a once-daily oral tablet which targets multiple pathways involved in the growth of tumours. Cabozantinib has been shown to significantly extend progression free survival compared with […]

read more

Treatment of metastatic kidney cancer in older patients

A recent meta-analysis evaluating the efficacy of first- and second-line treatment in older metastatic renal cell carcinoma (mRCC) patients (65 years or older) and comparing efficacy between older and younger (less than 65 years) patients, reports that the majority of first-line treatments are not as effective in older patients. The data suggest that a combination of […]

read more

NICE set to decline first-line cabozantinib for advanced kidney cancer

The National Institute for Health and Care Excellence (NICE) have issued an interim decision not to recommend cabozantinib (Cabometyx®) as a first-line treatment for advanced kidney cancer, despite it’s proven effectiveness at prolonging the life of kidney cancer patients. In their Appraisal Consultation Document (ACD) released this week, NICE have made the decision cabozantinib is too expensive to be prescribed […]

read more

European Commission approves cabozantinib for first-line kidney cancer

The European Commission has approved cabozantinib (Cabometyx) for the first-line treatment of advanced renal cell carcinoma (RCC).  The approval is based on data from the CABOSUN trial, which demonstrated that cabozantinib significantly prolongs progression-free survival (PFS) compared to sunitinib in people with untreated advanced RCC at intermediate or poor-risk of the cancer spreading. Cabozantinib, a […]

read more

Cabozantinib significantly improves overall survival in people with previously treated advanced kidney cancer

Cabozantinib significantly improves overall survival in previously treated patients with advanced renal cell carcinoma (RCC) compared to everolimus, with consistent results after long-term follow-up. Results from a second interim analysis of the phase 3 METEOR trial have been published in the British Journal of Cancer, showing cabozantinib significantly improved overall survival compared with everolimus in […]

read more

FDA grants Fast Track designation to glutaminase inhibitor combination for metastatic kidney cancer

The glutaminase inhibitor, CB-839 has been granted Fast Track designation by the US Food and Drug Administration (FDA) in combination with cabozantinib (Cabometyx) for the treatment of people with metastatic renal cell carcinoma (mRCC) who have previously received one or two drug treatments. The FDA’s Fast Track programme speeds up the development, review and approval […]

read more
Showing 21 to 30 of 66 results
  TOP